GW Succeeding With Cannabinoid Drug This Time Around
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug candidates targeting the cannabinoid receptors have a spotty past, so GW's successful Phase III data in pediatric epilepsy meets with great investor enthusiasm.
You may also be interested in...
GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids
Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.
Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.
Advisory Committee Unanimously Rejects Sanofi’s Zimulti
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously votes against approval of Sanofi-Aventis’ rimonabant for a weight loss indication.